Format

Send to

Choose Destination
Cancer Discov. 2020 Feb;10(2):OF8. doi: 10.1158/2159-8290.CD-RW2019-188. Epub 2019 Dec 20.

Asciminib Is Tolerable and Effective in Refractory Chronic Myeloid Leukemia.

[No authors listed]

Abstract

Asciminib was tolerable and had preliminary evidence of efficacy in chronic myeloid leukemia (CML).

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center